<DOC>
	<DOC>NCT01538212</DOC>
	<brief_summary>This evaluation of the efficacy and safety of AXONA will be a chart review carried out at 16 practices in which AXONA has been prescribed for the treatment of patients with mild-to-moderate AD. Efficacy of AXONA will be assessed by comparison of patient status before and after initiation of treatment.</brief_summary>
	<brief_title>Retrospective Cohort Study Of The Efficacy Of Axona® (Medium Chain Triglycerides) In Patients With Alzheimer's Disease</brief_title>
	<detailed_description>The primary objective is to assess the efficacy of AXONA (medium chain triglycerides [MCTs]) when used alone or in combination with other agents in patients with mild-to-moderate Alzheimer's disease (AD) in routine clinical practice.</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patient Male or female outpatients aged ≥ 50 years with a diagnosis of probable AD of mildtomoderate severity MMSE score between 14 and 24 inclusive at the initiation of AXONA treatment (if available) Has received Axona for a duration of ≥ 6 months Caregiver Inclusion Criteria (if applicable): Must be at least 21 years of age, has been the primary caregiver since prior to the initiation of Axona, provides at least 4 hours of supervision or direct assistance per day for the patient and is able to perform assessments. Patient MMSE score &lt; 14 at the time when AXONA treatment was initiated Presence of comorbid disease known to adversely impact cognitive function (e.g., Parkinson's disease, history of cerebral infarcts, dementia with Lewy bodies) Vascular dementia</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Alzheimer's disease</keyword>
	<keyword>retrospective</keyword>
	<keyword>Axona</keyword>
</DOC>